INTRODUCTION AND OBJECTIVES: Transrectal ultrasoundguided (TRUS) biopsy is the gold standard for prostate cancer diagnosis. This invasive procedure is generally associated with pain and discomfort. Currently, the periprostatic nerve block is the most used technique for pain control. However, there is still some controversy about where and what type of analgesic should be performed. The aim of this study was to evaluate the benefit of adding local periapical prostatic anesthesia to the traditional periprostatic nerve block during TRUS biopsy.
METHODS: A prospective study was performed and a total of 70 patients with indication for TRUS biopsy were enrolled. Patients were randomized into 2 groups. The control group received 5 ml of 1% lidocaine at the junction of the prostate with seminal vesicles bilaterally. The other group, which is referred from now on as the "periapical group" received 3 ml of 1% lidocaine at the junction of the prostate with seminal vesicles and 2 ml of the same anesthetic at the prostatic apex bilaterally. The pain experienced during different moments of the procedure (introduction of the ultrasound probe, anesthesia administration, removal of prostatic fragments and 30 minutes after finishing biopsy) was assessed using visual analog scales of one to ten. The rate of complications at 30 days post-biopsy was also assessed.
RESULTS: There were no significant differences concerning age, level of total PSA and prostate volume and pathological findings (detection of malignancy and positive cores) in both groups. The difference in pain during the distinct moments of TRUS biopsy was not significant between the two groups. Particularly, during the administration of anesthesia, the pain levels were similar, with a mean of 1,92 in the periapical group and 1,63 in the control group (p[0.772). No statistically significant differences were observed between the groups regarding the occurrence of complications, most importantly hematuria and/or urethral bleeding (7 patients (20%) in the control group and 5 (14,3%) in the periapical group; p[0,520).
CONCLUSIONS: Periprostatic and periapical nerve block does not improve pain control when compared to the periprostatic nerve block alone.
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MP13-13 ROBOTIC TRANSRECTAL COMPUTED TOMOGRAPHIC ULTRASOUND WITH ARTIFICIAL NEURAL NETWORK ANALYSIS e FIRST VALIDATION AND COMPARISON WITH MRI-GUIDED BIOPSIES AND RADICAL PROSTATECTOMY
Niklas Harland*, T€ ubingen, Germany; Giorgio Ivan Russo, Catania, Italy; Joachim Mathes, Steffen Rausch, Eva Neumann, Sascha Kaufmann, Arnulf Stenzl, Jens Bedke, T€ ubingen, Germany; Stephan Kruck, Pforzheim, Germany INTRODUCTION AND OBJECTIVES: Despite the growing evidence supporting MRI in prostate cancer (PC) diagnosis, there is still a lack of fast, cheap and accurate imaging tools to rule out significant PC (csPC). Consequently, we developed a new imaging method based on computed tomographic (CT) ultrasound (US) supported by artificial neural network analysis (ANNA).
METHODS: 202 consecutive patients in primary or re-biopsy setting with visible mpMRI (axial 3mm slices) lesions (PIRADS V2) were scanned and recorded by robotic CT-US (axial 0.5mm slices) as part of robot-assisted elastic mpMRI-TRUS fusion biopsy (RA-FB). Only significant index lesion (Gleason Score !3þ4) verified by biopsy and whole-mount pathology after radical prostatectomy (RP) were retrospectively analyzed. Their visibility was reevaluated by two blinded investigators by gray-scale US and ANNA.
RESULTS: In the whole cohort, csPC was detected in 105 cases (52%) by RA-FB. Whole-mount histology after RP was available in 44 cases (36%). In this subgroup mean PSA level was 8.6 ng/ml, mean prostate volume was 33 cc and mean tumor volume was 0.5 cc. Median PIRADS of index lesions was 4 and median Gleason Group was 3 based on biopsy and final histology. pT3 was found in 7 cases (16%). Index lesions were visible in gray-scale US in 25 cases (57%). Use of ANNA tool we identified index lesions in 30 cases (68%) while combining CT-US-ANNA we detected index lesions in 35 patients (80%).
CONCLUSIONS: First results of multiparametric computed ultrasound imaging showed promising detection rates, using grayscale and ANNA, in patients with csPC selected by RA-FB. In the near future, precise axial US imaging with reduced slice thickness and availability of complete US prostate scans for ANNA have the potential to revolutionize PC diagnosis.
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MP13-14 ANTIBIOPROPHYLAXIS FOR TRANSRECTAL ULTRASOUND-GUIDED PROSTATE NEEDLE BIOPSY: IS PREVENTION OF POST-PROCEDURAL URINARY SEPSIS IMPROVED WITH THE NOVEL COMBINATION OF CIPROFLOXACIN AND FOSFOMYCIN?
Alexandre Morin*, Sherbrooke, Canada; Marco Bergevin, Nathalie Rivest, Laval, Canada; Steven P Lapointe, Mont-Royal, Canada INTRODUCTION AND OBJECTIVES: Fluoroquinolones are recommended as first line antibioprophylaxis (ATBPx) for transrectal ultrasound-guided prostate needle biopsy (PNB). Recent studies report rising rates of post-PNB infections associated with emergent fluoroquinolone resistant E. coli, urging re-evalutation of ATBPx. The objective of this study was to compare rates of post-PNB sepsis associated with 2 oral regimens of ATBPx: a single dose of ciprofloxacin 500 mg (CIP) vs single dose of ciprofloxacin 500 mg and fosfomycin 3 g combination (CIP/FOS).
METHODS: We performed a retrospective, pre-post intervention study on all patients who underwent PNB in 2 Canadian hospitals from January 2012 to December 2015. ATBPx was changed from CIP to CIP/FOS in December 2013. ATBPx was administered two hours prior to PNB, along with a sodium phosphate enema. Patient charts were reviewed for hospital visits, microbiologic results, and 14 recognized risk factors for post-PNB infectious complications. The primary outcome was urosepsis within 1 month of PNB. Sepsis rates, according to ATBPx regimens, were analyzed using log-binomial regression considering the propensity scores weights of collected risk factor data.
RESULTS: We reviewed charts of 2,287 patients, including 1090 who received CIP alone and 1197 who received CIP/FOS. Urosepsis incidence with CIP alone was 1.1% (12/1090) and fell to 0.2% (2/ 1197) with CIP/FOS. Our analysis indicates that CIP/FOS significantly decreased the risk of sepsis compared to CIP alone (aRR [ 0.16; p [ 0.021). The pathogen was E. coli in 12/14 cases, with 7 CIP resistant strains. Most E. coli (11/12) were from CIP alone group. We observed 7 cases of E. coli bacteremia, with 5/7 blood cultures showing CIP resistant strains. One case of B. fragilis septicemia occurred in the CIP/FOS group. No cases of C. difficile diarrhea were identified within the 3 months post-PNB.
